Titlebook: New Therapeutic Targets in Rheumatoid Arthritis; Paul-Peter Tak Book 2009 Birkh?user Basel 2009 Arthritis.Chemokine.Drug Target.Interleuki

用肘

冷淡周邊

LATER

Interleukin-15, adaptive immune system. It binds to a heterotrimeric receptor consisting of the common γ-chain receptor, IL-15/IL-2 receptor β-chain and unique IL-15 receptor α-chain. IL-15 is expressed at the mRNA level in a variety of cell lineages and is expressed as protein as part of the rapid early inflammat

Leaven

IL-17 and Th17 cells, key players in arthritis,rged as the best-studied situation to justify the selection of IL-17 as a therapeutic target. By interacting with other proinflammatory cytokines, IL-17 was found to induce bone and cartilage destruction. In 2006, the precise cell source of IL-17 was identified in the mouse. These cells were named T

要塞

巨大沒有

創(chuàng)新

預(yù)防注射

farewell

招募

Perspectives in targeted therapy,lity of animal models for development of targeted therapies, clinical trial design, pharmacodynamics, immunobiology and key pathogenic elements of disease. Studies of chimeric anti-CD4 monoclonal antibodies in RA demonstrated the need for pre-clinical studies to more closely approximate the human th